rHGH and Intestinal Permeability in Intestinal Failure

Phase

Condition

Bowel Dysfunction

Treatment

N/A

Clinical Study ID

NCT01380366

STU00012123 0208-007

CNV0050754

Ages 18-80
All Genders

Study Summary

Patients who are being asked to participate in this study have a short small bowel and will be prescribed to take the medication: Zorbtive® ("Zorbtive/Somatropin/(rHGH)"). Zorbtive® is an FDA approved recombinant human growth hormone (rHGH). The investigators want to see if taking this medication improves small bowel function by helping it to take in food, nutrients, vitamins and minerals. The investigators also believe that if the small bowel is absorbing food and nutrients better, liver function will improve as well. Therefore, liver function will also be monitored during the course of the study by performing blood tests.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Subjects must be between the ages of 18 and 80
Subjects can be male or female
Subjects must have short bowel syndrome with <200cm of functional small bowel or havesevere small bowel dysfunction mandating regular (at least two times per week)administration of total parenteral nutrition (TPN) and/or IV fluids.
Subjects must have been dependent on TPN or IV fluids for 1 year, or are expected tobe dependent on TPN or IV fluids for at least 1 yr.
Subjects must be patients being seen in the Northwestern intestinal failure clinic
Subjects must be willing to spend one night in the Clinical Research Center
Subjects must be able to read, understand and be able to sign the study specificinformed consent

Exclusion

Exclusion Criteria:

Subjects must be greater than or equal to 18 years of age, but less than or equal to 80 years of age
Infections requiring antibiotic therapy within one week of starting the study
Subjects must not have evidence of an ongoing malignancy for two years
Subjects must not have history of antibiotic use within one week of initiating thestudy. Subjects may enroll in the study as long as Visit 1 is at least one week fromthe last dose of antibiotics.
Subjects that have evidence of acute critical illness due to complications followingopen heart or abdominal surgery, multiple accidental trauma, or acute respiratoryfailure
Subjects with known liver disease, positive hepatitis B virus (HBV), or hepatitis Cvirus (HCV) serology
Subjects unwilling to abstain from alcohol 7 days prior to and during the 28 days ofZorbtive® therapy, until completion of Visit 2
Subjects with a known sensitivity to Benzyl Alcohol
Subjects with a known sensitivity to growth hormone
Female subjects that are unable or unwilling to use effective, acceptable birthcontrol methods throughout the study and for up to 6 months after completing treatmentwith Zorbtive therapy
Female subject with a positive pregnancy test

Study Design

October 01, 2006

February 28, 2015

Study Description

This is an open-label pilot study in which a convenience sample of 20 subjects will participate for up to 26 months.

At the baseline visit, subjects will sign a consent form after all questions they have are answered. An inpatient appointment will be made at the General Clinical Research Center (GCRC). Subjects will be given instructions to fill out a 7-day food diary the week prior to their inpatient appointment. In this diary, subjects will be asked to record the types and amounts of food they ingest over a 7-day period. This will allow researchers to review subjects' food intake prior to sugar permeability testing. Although each subject serves as his/her own control, this information may be useful upon review of variations in permeability between subjects.

To evaluate the potential hepato-protective effects of improving intestinal barrier function, blood tests evaluating liver injury and function (i.e. ALT, AST, total bilirubin, ALP, GGT) will be obtained. These labs are part of the subject's standard of care follow-up, therefore study staff will abstract these data from the subject's medical record. The sugar permeability testing requires an 8-hour overnight fast, followed by the ingestion of 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. Over the next 5 hours, urine is collected. Intestinal permeability is quantified as the urine ratio of lactulose, mannitol and sucralose. After urine collection is complete, subjects will begin their 28 days of Zorbtive® administration.

All evaluations (subject food diary, bloodwork, and sugar permeability testing) will be repeated 28 days later, within 72 hours of receiving the final dose of Zorbtive®. The bloodwork drawn is part of the subject's standard of care follow-up, therefore study staff will abstract these data from the subject's medical record.

Following completion of study visits at the GCRC, study staff will obtain results of liver injury/ function tests [(ALT), (AST), bilirubin, alkaline phosphatase (ALK or ALP), (GGT)] from the medical record from each routine clinical exam from Month 3 through Month 24, following the 28-day treatment with Zorbtive® therapy. These labs are part of the subject's standard of care follow-up, therefore study staff will abstract these data from the subject's medical record. Subjects will not be asked to return for separate study visits.

Since the intestinal epithelium is completely reconstituted approximately every 7 days, it is anticipated that the potential influences of rHGH on barrier function and related liver injury will be realized by the end of the 28 day study period. The long term durability of any changes observed after 28 days will be observed, but will likely require further study.

Connect with a study center

Northwestern Memorial Hospital
Chicago, Illinois 60611
United States
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.